Semaglutide and tirzepatide are the two active ingredients behind most of the medications people mean when they say "GLP-1 shot": Ozempic®, Wegovy®, Mounjaro®, Zepbound™, and their compounded counterparts. They're related, they're often discussed in the same breath, and they're sometimes treated as interchangeable in casual conversation. They aren't quite the same thing. This article walks through how the two molecules work, how they're typically dosed, what head-to-head research has found, and how a clinician generally thinks about choosing between them.
The confusion is understandable. Both medications are injected weekly, both are started at a low dose and increased over time, and both are used for similar goals: appetite reduction, weight management, and blood sugar control. The practical differences that do exist, including how each is dosed and what clinical trials have found when researchers compared them directly, are worth understanding before a conversation with a prescriber, even though the final decision about which medication, if either, is appropriate ultimately belongs to a licensed clinician.
This article is patient education, not medical advice. It does not create a doctor-patient relationship and is not a substitute for an individualized evaluation with a licensed clinician.
What semaglutide and tirzepatide are, and how their mechanisms differ
Semaglutide is a GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a hormone the gut releases after eating that signals the pancreas to release insulin, slows how quickly the stomach empties, and acts on appetite centers in the brain to increase feelings of fullness. Semaglutide is engineered to mimic that hormone and stay active in the body far longer than natural GLP-1 does, which is what allows once-weekly dosing. It's the active ingredient in Ozempic® and Wegovy®, both FDA-approved, as well as in compounded semaglutide preparations.
Tirzepatide works on the same GLP-1 receptor, but it's a dual agonist: it also activates the receptor for GIP, or glucose-dependent insulinotropic polypeptide, a second gut hormone involved in insulin release and appetite regulation. The addition of GIP activity is the main structural difference between the two molecules, and it's the reason tirzepatide is sometimes described as working through two hormone pathways instead of one. Tirzepatide is the active ingredient in Mounjaro® and Zepbound™, both FDA-approved, as well as in compounded tirzepatide preparations.
Despite the mechanistic difference, the practical effects of both medications overlap substantially: reduced appetite, slower gastric emptying, and improved blood sugar regulation. Most of what patients notice week to week, including how a dose feels and how side effects show up, tends to look similar between the two, even though the receptor biology isn't identical.
How each medication is typically dosed and administered
Both semaglutide and tirzepatide are most commonly prescribed as a once-weekly subcutaneous injection, and both are started at a low dose that's increased gradually over a period of weeks to months. That gradual titration is one of the most consistent features of GLP-1 and GLP-1/GIP treatment, and it exists specifically to give the digestive system time to adjust, which reduces the intensity of gastrointestinal side effects compared with starting at a higher dose right away.
The FDA-approved brand products come as prefilled injection pens designed for at-home use, with each pen typically delivering one weekly dose. Compounded formulations of either medication may also be available as oral troches, sublingual preparations, or other delivery methods depending on the prescribing pharmacy, which is a separate question from the molecule itself. You can read more about how those formats compare in our article on oral vs. injectable GLP-1 medications. Whichever format is used, dose changes are generally made no more often than every four weeks, giving the body time to adjust to each step before moving to the next.
The table below is a general educational overview, not a prescribing guide. Actual starting doses, titration schedules, and maximum doses are set by a prescribing clinician based on an individual evaluation, and they can differ from what's typical depending on tolerability and clinical goals.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptor activity | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| FDA-approved brands | Ozempic®, Wegovy® | Mounjaro®, Zepbound™ |
| Typical dosing frequency | Once weekly, subcutaneous injection | Once weekly, subcutaneous injection |
| Dose titration | Started low, increased gradually over weeks to months | Started low, increased gradually over weeks to months |
| Common side effects | Nausea, diarrhea, vomiting, constipation | Nausea, diarrhea, vomiting, constipation |
| Compounded availability | Yes, not FDA-approved | Yes, not FDA-approved |
What clinical research says about weight loss and blood sugar effects
Semaglutide and tirzepatide have each been studied extensively in large clinical trials, both on their own and, more recently, against each other directly. Individually, both molecules are well established to reduce appetite, support weight loss when combined with a reduced-calorie diet and increased physical activity, and improve blood sugar control in people with type 2 diabetes.
Clinical trials that compared the two medications directly have generally found that tirzepatide was associated with somewhat greater average weight loss than semaglutide, though individual results vary widely from person to person. Some researchers attribute this to the added GIP receptor activity, though the exact reasons aren't fully settled. It's worth being cautious about reading too much into average trial results: a population-level average doesn't predict how any one individual will respond, and factors like starting weight, dose tolerated, diet, activity level, and other health conditions all affect outcomes.
Neither medication's effectiveness is guaranteed for any individual patient, and clinical trial results describe averages across large groups of participants, not a promise about what any single person will experience. The Endocrine Society and the American Diabetes Association both note that GLP-1-based therapies are one part of a broader approach to weight and metabolic health, not a stand-alone solution.
How side effects compare between the two
Because semaglutide and tirzepatide affect the digestive system in similar ways, their side effect profiles overlap heavily. The most commonly reported side effects for both are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion. These tend to be most noticeable during dose increases and often ease as the body adjusts, which is a large part of why gradual titration is standard practice for both medications. You can read a more detailed breakdown in our article on side effects of GLP-1 medications.
Some clinical trial data suggests tirzepatide's dual mechanism may, for some patients, come with a somewhat different side effect intensity than semaglutide, though the overall categories of side effects reported are similar. Neither medication is free of side effects, and "side-effect-free" isn't a realistic expectation for either one.
Both medications carry the same boxed warning regarding thyroid C-cell tumors observed in rodent studies, and neither is recommended for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A full list of warnings and precautions is included in the Important Safety Information below, and a prescribing clinician will review your personal and family medical history before recommending either medication.
Compounded versions vs. FDA-approved brand products
Ozempic® and Wegovy® are the FDA-approved brand names for semaglutide; Mounjaro® and Zepbound™ are the FDA-approved brand names for tirzepatide. Compounded medications, including compounded semaglutide and compounded tirzepatide, are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality; they may be prescribed by an independent licensed physician when clinically appropriate, such as during an FDA-declared shortage or to meet a specific patient need, for example a different dose strength or delivery method. You can read more in our separate articles on what compounded semaglutide is and what compounded tirzepatide is.
Choosing between a brand-name product and a compounded formulation is a separate decision from choosing between semaglutide and tirzepatide as molecules, and both questions are worth raising with a prescribing clinician. Cost, insurance coverage, supply availability, and the specific formulation a pharmacy offers can all factor into that conversation.
How a clinician decides which may be appropriate for you
There's no single answer to whether semaglutide or tirzepatide is the "right" choice, because the decision depends on the individual. A prescribing clinician typically considers factors including your overall health history, any other medical conditions such as type 2 diabetes, current medications, prior experience with either drug class, tolerability of gastrointestinal side effects, and your personal goals.
An online evaluation doesn't guarantee that either medication will be prescribed. An independent licensed clinician reviews your history and determines whether treatment with semaglutide, tirzepatide, or neither is appropriate for you, and that decision is made individually rather than by simply picking the option with the larger average effect in a trial. In some cases, a clinician may also start with one medication and revisit the choice later based on how you respond, since tolerability and results can only be assessed once treatment is actually underway.
It's also worth remembering that neither medication works in isolation. Both are intended to be used alongside a reduced-calorie diet and increased physical activity, and a clinician's recommendation typically accounts for how ready and able you are to make those complementary changes, not just which molecule might produce a larger average result in published research.
For a broader look at who is generally considered for this category of treatment, see our article on who is eligible for medical weight management.
The bottom line
Semaglutide and tirzepatide are related but distinct medications: both work through the GLP-1 pathway, and tirzepatide adds activity at a second hormone receptor, GIP. In practice, they share similar dosing patterns, similar categories of side effects, and similar clinical uses, though head-to-head research has generally found tirzepatide associated with somewhat greater average weight loss. Neither outcome is guaranteed for any individual, and the right choice between them, including whether a brand-name or compounded formulation makes sense, is a conversation to have with a licensed clinician who can review your full health history.
You can find more on related topics in our Weight Management section.
Important Safety Information
Indication. Semaglutide is a GLP-1 receptor agonist, and tirzepatide is a dual GIP and GLP-1 receptor agonist. Both are used, when clinically appropriate, to support blood sugar management or chronic weight management alongside a reduced-calorie diet and increased physical activity. FDA-approved brands include Ozempic® and Wegovy® (semaglutide) and Mounjaro® and Zepbound™ (tirzepatide). Compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality; they may be prescribed by an independent licensed physician when clinically appropriate.
Common side effects. The most commonly reported side effects for both medications are gastrointestinal, including nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion. These are often mild and tend to ease over time, especially as the dose is increased gradually.
Warnings. Both medications carry a boxed warning regarding thyroid C-cell tumors seen in rodent studies. Do not use either if you or a family member has had medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider about any history of pancreatitis, gallbladder disease, or kidney problems, or if you are pregnant, planning to become pregnant, or breastfeeding.
Talk to your doctor. This information is educational and is not a substitute for medical advice. Only a licensed medical professional can determine whether a treatment is right for you. Talk to your doctor about the benefits and risks, and report any side effects.
Frequently asked questions
Is tirzepatide "better" than semaglutide for weight loss?
Clinical trials that have compared the two medications directly have generally found tirzepatide associated with somewhat greater average weight loss, likely related to its added GIP receptor activity. That is a population-level average, though; individual results vary widely, and neither medication's effect on any one person can be predicted from a trial average alone.
Can I switch from semaglutide to tirzepatide, or the other way around?
Switching between the two is something some patients do, but it should only happen under the guidance of a prescribing clinician, who can advise on timing, dosing, and what to expect. It is not a decision to make on your own by changing which prescription you fill.
Do semaglutide and tirzepatide have the same side effects?
Their side effect profiles overlap substantially, since both slow digestion and act on related pathways. The most common side effects for both are gastrointestinal, including nausea, diarrhea, vomiting, and constipation. Neither medication is free of side effects, and how any individual tolerates either one can only be determined during treatment.
Are compounded semaglutide and tirzepatide the same as Ozempic®, Wegovy®, Mounjaro®, and Zepbound™?
They contain the same active molecule, but compounded versions are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality, unlike the FDA-approved brand products. Compounded medications may be prescribed by an independent licensed physician when clinically appropriate, such as during a supply shortage.
How does a clinician decide which medication to prescribe?
A prescribing clinician considers your overall health history, any other conditions such as type 2 diabetes, current medications, past experience with either drug class, and your personal goals. An online evaluation does not guarantee that any specific medication will be prescribed.
Can I request tirzepatide or semaglutide specifically?
You can share your preference with a prescribing clinician, and it is a reasonable topic to raise during an evaluation. An independent licensed clinician ultimately determines what is clinically appropriate for you based on your individual health history, not solely on patient preference.
